Ophthalmologica

Original Paper

Dexamethasone Intravitreal Implant Therapy for Retinal Vein Occlusion Macular Oedema and Conversion to Ranibizumab in Clinical Practice

Balal S.a · Than J.b · Tekriwal S.a · Lobo A.a

Author affiliations

aMoorfields Eye Hospital, Bedford, and bLuton and Dunstable University Hospital, Luton, UK

Keywords: Retinal vein occlusionDexamethasoneRanibizumabLucentisOzurdexMacular oedema

Related Articles for ""
Ophthalmologica 2018;239:36-44
https://doi.org/10.1159/000479893

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates

Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: March 08, 2017
Accepted: July 27, 2017
Published online: September 27, 2017
Issue release date: December 2017

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 6

ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)

For additional information: https://www.karger.com/OPH

Abstract

Purpose: Evaluation of outcomes in retinal vein occlusions (RVOs) for: (1) multiple repeat dexamethasone (DEX) injections and (2) conversion from DEX to ranibizumab. Methods: We conducted a retrospective study evaluating outcomes of multiple DEX injections and those requiring conversion to ranibizumab at Moorfields Eye Hospital, Bedford, UK. All patients had undergone a complete ophthalmic work-up. Results: Patients (n = 129) had a mean follow-up of 19.9 months. The mean improvement in central retinal thickness was 312 μm after final DEX (p = <0.0001). Mean peak best corrected visual acuity (BCVA) after final DEX was an improvement of 16 ETDRS letters (p < 0.0001). Forty-nine patients were converted and received a mean of 9.37 ranibizumab injections with a mean improvement in BCVA of 15 ETDRS letters (p < 0.0001) compared with final DEX. Conclusions: This study supports the use of ranibizumab in eyes previously treated with DEX and provides long-term efficacy and safety data for multiple DEX injection.

© 2017 S. Karger AG, Basel



Related Articles:

References

  1. Rogers S, McIntosh RL, Cheung N, Lim L, et al: The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313-319.e1.
  2. Bressler NM, Schachat AP: Management of macular edema from retinal vein occlusions: you can never have too many choices. Ophthalmology 2010;117:1061-1063.
  3. Haller JA, Bandello F, Belfort R, Blumenkranz MS, et al: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146.e13.
  4. Capone Jr A, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, Walt JG, Scott LC, Hollander DA: Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina 2014;34:342-351.
  5. Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, Cascavilla ML, Bandello F: Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. Ophthalmologica 2012;229:21-25.
  6. Joshi L, Yaganti S, Gemenetzi M, Lightman S, Lindfield D, Liolios V, Menezo V, Shao E, Taylor SR: Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol 2013;97:1040-1044.
  7. Bakri SJ, Omar AF, Iezzi R, Kapoor KG: Evaluation of multiple dexamethasone intravitreal implants in patients with macular edema associated with retinal vein occlusion. Retina 2016;36:552-557.
  8. Brown DM, Campochiaro PA, Singh RP, Li Z, et al: Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124-1133.e1.
  9. Campochiaro PA, Heier JS, Feiner L, Gray S, et al: Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-1112.e1.
  10. Ashraf M, Souka A, Singh R: Central retinal vein occlusion: modifying current treatment protocols. Eye 2016;30:505-514.
  11. Campochiaro PA, Choy DF, Do DV, Hafiz G, Shah SM, Nguyen QD, Rubio R, Arron JR: Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology 2009;116:2158-2164.
  12. Cohen MN, Houston SK, Juhn A, Ho AC, Regillo CD, Vander J, Chiang A: Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion. Can J Ophthalmol 2016;51:342-347.
  13. Rahimy E, Shahlaee A, Khan MA, Ying G-S, Maguire JI, Ho AC, Regillo CD, Hsu J: Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol 2016;164:118-127.e2.
  14. Manousaridis K, Peter S, Mennel S: Outcome of intravitreal dexamethasone implant for the treatment of ranibizumab-resistant macular edema secondary to retinal vein occlusion. Int Ophthalmol 2017;37:47-53.
  15. Alshareef RA, Garg SJ, Hsu J, Vander J, Park C, Spirn MJ: Intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion persisting despite multiple intravitreal bevacizumab injections. J Ocul Pharmacol Ther 2014;30:512-516.
  16. Wong V: Retinal venous occlusive disease. Hawaii Med J 1997;56:289-291.
  17. Bezatis A, Spital G, Höhn F, Maier M, Clemens CR, Wachtlin J, Lehmann F, Hattenbach LO, Feltgen N, Meyer CH: Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up-The SOLO study. Acta Ophthalmol 2013;91:e340-e347.
  18. Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A, Group RS: Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 2014;121:209-219.
  19. Gregori NZ, Feuer W, Rosenfeld PJ: Novel method for analyzing Snellen visual acuity measurements. Retina 2010;30:1046-1050.
  20. Dugel PU, Capone A, Singer MA, Dreyer RF, Dodwell DG, Roth DB, Shi R, Walt JG, Scott LC, Hollander DA: Two or more dexamethasone intravitreal implants in treatment-naïve patients with macular edema due to retinal vein occlusion: subgroup analysis of a retrospective chart review study. BMC Ophthalmol 2015;15:118.
  21. Singer MA, Capone A Jr, Dugel PU, Dreyer RF, Dodwell DG, Roth DB, Shi R, Walt JG, Scott LC, Hollander DA: Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study. BMC Ophthalmol 2015;15:1.
  22. Scott IU, Ip MS, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, Chan CK, Gonzalez VH, Singerman LJ, Tolentino M: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115.
  23. Larsen M, Waldstein SM, Boscia F, Gerding H, Monés J, Tadayoni R, Priglinger S, Wenzel A, Barnes E, Pilz S: Individualized ranibizumab regimen driven by stabilization criteria for central retinal vein occlusion: twelve-month results of the CRYSTAL study. Ophthalmology 2016;123:1101-1111.
  24. Mones J: Evaluation of ranibizumab for macular ischemia in retinal vein occlusion: evidence from the BRIGHTER and CRYSTAL studies. Invest Ophthalmol Vis Sci 2015;56:5803-5803.
  25. Nghiem-Buffet S, Baillif S, Regnier S, Skelly A, Yu N, Sodi A: Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA. Eye 2017;31:551-559.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: March 08, 2017
Accepted: July 27, 2017
Published online: September 27, 2017
Issue release date: December 2017

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 6

ISSN: 0030-3755 (Print)
eISSN: 1423-0267 (Online)

For additional information: https://www.karger.com/OPH

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

2018, Vol.239, No. 1

December 2017

Article

Recommend This
TOP